Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
OncoFusion Therapeutics, an oncology drug company formed in 2012 by two University of Michigan professors, has signed a licensing agreement with the San Francisco-based biotech firm Medivation. The deal gives Medivation rights to develop and commercialize compounds discovered by OncoFusion that target bromodomain and extraterminal proteins, which regulate genes and play a role in cancer. Medivation is involved in a lawsuit with professors from the University of California, Los Angeles, over a similar compound licensing agreement (C&EN, April 21, page 8).
This article has been sent to the following recipient: